Furazolidone treatment of cutaneous leishmaniasis

J. M. L. Costa, R. N. Sampaio, M. S. Tada, E. A. Almeida, E. P. Veiga, A. V. Magalhåes and P. D. MARSDEN

Tropical Medicine Unit, University of Brasília, Brasília, Brazil

BERMAN & LEE (1983) reported a high antileishmanial activity for furazolidone against amastigotes in human macrophages and suggested a clinical trial with this drug. In vitro it was six times more effective than nifurtimox, a drug we have investigated in human leishmaniasis (MARSDEN et al., 1979; GUERRA et al., 1981). At a time when glucantime was not available furazolidone was given to eight patients with

done is a very different situation to this small clinical study. To date it has not been possible to do in vitro tests with L. braziliensis braziliensis since it does not adapt to the macrophage system. Furazolidone is poorly absorbed and only about 5% of an oral dose appears in the urine (M. S. Wolfe, personal communication). Probably this is a factor accounting for our poor results.

Table—Results	of	Furazo	lidone	treatment
---------------	----	--------	--------	-----------

	Before treatment				After treatment		
Patient number	Leishmanin skin test	Amastigotes detected	Immuno- fluorescent antibody titre	Amastigotes detected	Clinical result*		
1	Neg	+	1:40	+	A		
2	+	+	1:80	+	Α		
3	+	+	1:80	0	Α		
4	Neg	+	0	+	Α		
5	+	+	1:80	-	Α		
6	+	+	1:40	_	Α		
7	+	+	1:320		Ĥ		
8	+	-	0		Ā		

*1 month after cessation of treatment A-active H-healed

improvement patients received glucantime which was then available. The results are set out in the table. All patients had histology compatible with leishmaniasis and amastigotes were observed in most patients. The leishmanin skin test and fluorescent antibodies to Leishmania were positive in most patients. Seven patients failed to respond to furazolidone and parasites were seen in three of four biopsies after treatment. The one patient who healed after the drug had a significant fall in the fluorescent antibody titre seven months later (1:40). This could be the result of furazolidone therapy or simply the natural evolution of the disease, since spontaneous cure is common even with L. braziliensis braziliensis infections (MARSDEN et al., 1984).

Furazolidone is widely used in the USA for the treatment of giardiasis, especially in children (WEB-STER, 1960; CRAFT et al., 1981). From our results it does not benefit patients with cutaneous leishmaniasis in the same way as does glucantime (LLANOS-CUENTAS et al., in press). These seven patients who failed to heal responded to glucantime therapy (20mg Sb^v/kg body-weight for 30 days).

Evidently L. tropica tested in vitro against furazoli-

References

- Berman, J. D. & Lees, L. S. (1983). Activity of oral drugs against Leishmania tropica in human macrophages in vitro. American Journal of Tropical Medicine and Hygiene,
- 32, 947-951. Craft, J. C., Murphy, T. & Nelson, J. D. (1981). Furazolidone and Quinacrine. a comparative study of therapy for giardiasis in children. American Journal of Diseases of Children, 135, 164-166. Guerra, M. F. V., Marsden, P. D., Cuba, C. C. & Barreto,
- A. C. (1981). Further trials of Nifurtimox in mucocu-
- tancous leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 75, 335-337.
 Llanos-Cuentas, E. A., Marsden, P. D., Lago, E. L., Barreto, A. C., Cuba, C. C. & Johnson, W. D. (1984). Human mucocutaneous leishmaniasis in Três Bracos, Bahia-Brazil. An area of Leishmaniasis braziliensis braziliensis. II. Cutaneous disease: presentation and evolution. Revista de Sociedade Brasileira de Medicina Tropical, 17, 169-177
- Marsden, P. D., Cuba, C. C., Barreto, A. C., Sampaio, R. N. & Rocha, R. A. A. (1979). Nifurtimox in the treatment of South American leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 73, 392-394
- Marsden, P. D., Tada, M. S., Barreto, A. C. & Cuba, C. C. (1984). Spontaneous healing of Leishmania braziliensis braziliensis skin ulcers. Transactions of the Royal Society of Tropical Medicine and Hygiene, 78, 561-562.
- giardiasis. American Journal of Digestive Diseases, 5, 618-612. Webster, B. H. (1960). Furazolidone in the treatment of

Accepted for publication 12th November, 1984.

cutaneous leishmaniasis of one to six months duration in an area in which Leishmania braziliensis braziliensis is the dominant parasite infecting man. A daily divided oral dose totalling 8 mg/kg body-weight was given for 10 days and this course repeated within a month. After a further month if there was no